

**SAL Laboratories Limited**  
**Annual report and unaudited financial statements**  
**for the year ended 31 December 2019**

Registered number: NI 017168

SATURDAY



A14 \*A9DXTEEQ\* 19/09/2020 #167  
COMPANIES HOUSE

# **SAL Laboratories Limited**

## **Contents**

	<b>Page</b>
Directors' report	3
Statement of financial position	4
Notes to the financial statements	5

# **SAL Laboratories Limited**

## **Directors' report**

The Directors present their report and the unaudited financial statements of SAL Laboratories Limited (the "Company") for the year ended 31 December 2019.

### **Principal activities and business review**

The Company has not traded during the current or prior period. The Directors do not expect that this position will change in the foreseeable future. The Company is a dormant company in terms of section 1169 of the Companies Act 2006.

### **Directors' responsibilities**

The Directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

### **Going concern**

As described in the accounting policies, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

### **Directors**

The Directors, who served throughout the year and thereafter, were as follows:

M Calderbank	(resigned 14 June 2019)
P McCluskey	(resigned 31 December 2019)
MJ Hanson	(appointed 3 June 2019)
Dr M Carnegie-Brown	(appointed 5 August 2019)

### **Exemption from audit**

For the year ended 31 December 2019, the Company was entitled to exemption from audit under section 480 of the Companies Act 2006. The members have not required the Company to obtain an audit of its accounts for the year, in accordance with section 476 of the Companies Act 2006.

Approved by the Board and signed on its behalf by:



MJ Hanson  
Director  
01 September 2020

## SAL Laboratories Limited

### Statement of financial position

As at 31 December 2019

	Note	2019 £	2018 £
<b>Current assets</b>			
Trade and other receivables	2	179,803	179,803
<b>Net assets</b>		<u>179,803</u>	<u>179,803</u>
<b>Capital and reserves</b>			
Called-up share capital	3	54,000	54,000
Profit and loss account		125,803	125,803
<b>Shareholders' funds</b>		<u>179,803</u>	<u>179,803</u>

Registered number: NI 017168

For the financial period ended 31 December 2019 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The Directors:

- confirm that members have not required the Company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- *acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.*

The financial statements of SAL Laboratories Limited were approved by the Board of Directors and authorised for issue on 01 September 2020. They were signed on its behalf by:



MJ Hanson

Director

# SAL Laboratories Limited

## Notes to the financial statements

As at 31 December 2019

### 1. Accounting policies

SAL Laboratories Limited (the "Company") is a company incorporated and domiciled in the UK.

#### Basis of preparation

These financial statements were prepared in accordance with Financial Reporting Standard 101 *Reduced Disclosure Framework* ("FRS 101").

The Company's ultimate parent undertaking, Spectris plc includes the Company in its consolidated financial statements. The consolidated financial statements of Spectris plc are prepared in accordance with International Financial Reporting Standards as adopted by the EU, and are available to the public as set out in note 4.

The financial statements are prepared on the historical cost basis.

These financial statements are presented in pounds sterling.

#### Going concern

The Company has not traded during the current period. The Directors do not expect that this position will change in the foreseeable future. The Directors expect to be able to operate within the level of its current resources to meet current obligations. Consequently, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

### 2. Trade and other receivables

	2019 £	2018 £
Amounts owed by Group undertakings	179,803	179,803

### 3. Called-up share capital

	2019 No.	2019 £	2018 No.	2018 £
<b>Allotted, called-up and fully-paid</b>				
Ordinary shares of £1 each	54,000	54,000	54,000	54,000

### 4. Ultimate parent and controlling party

At 31 December 2019, Spectris plc, a company listed on the London Stock Exchange was the ultimate controlling party by virtue of its 100% holding in the issued share capital of Concept Life Sciences (Holdings) Limited.

Spectris plc, is the largest and smallest group in which the results of the Company are consolidated. The consolidated accounts of this company may be obtained from Spectris plc, Heritage House, Church Road, Egham, Surrey, TW20 9QD.